Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach

Subhamay Adhikary,Surajit Pathak,Vignesh Palani,Ahmet Acar,Antara Banerjee,Nader I. Al-Dewik,Musthafa Mohamed Essa,Sawsan G. A. A. Mohammed,M. Walid Qoronfleh

DOI: https://doi.org/10.3390/biomedicines12010217

IF: 4.757

2024-01-19

Biomedicines

Abstract:Immunotherapy is now established as a potent therapeutic paradigm engendering antitumor immune response against a wide range of malignancies and other diseases by modulating the immune system either through the stimulation or suppression of immune components such as CD4+ T cells, CD8+ T cells, B cells, monocytes, macrophages, dendritic cells, and natural killer cells. By targeting several immune checkpoint inhibitors or blockers (e.g., PD-1, PD-L1, PD-L2, CTLA-4, LAG3, and TIM-3) expressed on the surface of immune cells, several monoclonal antibodies and polyclonal antibodies have been developed and already translated clinically. In addition, natural killer cell-based, dendritic cell-based, and CAR T cell therapies have been also shown to be promising and effective immunotherapeutic approaches. In particular, CAR T cell therapy has benefited from advancements in CRISPR-Cas9 genome editing technology, allowing the generation of several modified CAR T cells with enhanced antitumor immunity. However, the emerging SARS-CoV-2 infection could hijack a patient's immune system by releasing pro-inflammatory interleukins and cytokines such as IL-1β, IL-2, IL-6, and IL-10, and IFN-γ and TNF-α, respectively, which can further promote neutrophil extravasation and the vasodilation of blood vessels. Despite the significant development of advanced immunotherapeutic technologies, after a certain period of treatment, cancer relapses due to the development of resistance to immunotherapy. Resistance may be primary (where tumor cells do not respond to the treatment), or secondary or acquired immune resistance (where tumor cells develop resistance gradually to ICIs therapy). In this context, this review aims to address the existing immunotherapeutic technologies against cancer and the resistance mechanisms against immunotherapeutic drugs, and explain the impact of COVID-19 on cancer treatment. In addition, we will discuss what will be the future implementation of these strategies against cancer drug resistance. Finally, we will emphasize the practical steps to lay the groundwork for enlightened policy for intervention and resource allocation to care for cancer patients.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

What problem does this paper attempt to address?

The main issue this paper attempts to address is the application of current immunotherapies in clinical oncology and the challenges they face, particularly the problem of tumor resistance to immunotherapy. Specifically, the paper aims to:

1. **Review existing immunotherapy technologies**: Including monoclonal antibodies, natural killer (NK) cell therapy, dendritic cell (DC) vaccines, CAR T-cell therapy, etc.
2. **Explore the mechanisms of tumor resistance to immunotherapy**: Including primary resistance and secondary or acquired resistance, and how these mechanisms affect treatment efficacy.
3. **Analyze the impact of COVID-19 on cancer treatment**: Particularly how SARS-CoV-2 infection interferes with patients' immune systems and subsequently affects the efficacy of immunotherapy.
4. **Look ahead to future developments**: Propose strategies to overcome tumor resistance in the future and how to optimize existing immunotherapies.
5. **Policy recommendations**: Provide practical policy suggestions for interventions and resource allocation to improve the treatment and care of cancer patients.

Through discussions on these aspects, the paper hopes to provide a comprehensive review of immunotherapy in the field of clinical oncology and offer guidance for future research and clinical practice.